Accessibility Statement Skip Navigation
  • Back to Global Sites
  • +972-77-2005042
  • Blog
  • Journalists
  • GDPR
  • Send a Release
PR Newswire: news distribution, targeting and monitoring
  • News
  • Products
  • Contact
  • Hamburger menu
  • PR Newswire: news distribution, targeting and monitoring
  • Send a Release
    • Telephone

    • +972-77-2005042 from 8 AM - 11 PM IL

    • Contact
    • Contact

      +972-77-2005042
      from 8 AM - 11 PM IL

  • Request More Information
  • Journalists
  • GDPR
  • Request More Information
  • Journalists
  • GDPR
  • Request More Information
  • Journalists
  • GDPR
  • Request More Information
  • Journalists
  • GDPR

Amorphical brings Scientific Breakthrough - Treating and Curing Chronic Inflammatory and Oncological Diseases
  • USA - Deutsch
  • USA - Français
  • USA - English

Amorphical Logo (PRNewsfoto/Amorphical)

News provided by

Amorphical

27 Nov, 2023, 13:51 IST

Share this article

Share toX

Share this article

Share toX

NES-ZIONA, Israel, Nov. 27, 2023 /PRNewswire/ -- An exclusive initiative by the Israeli biotechnology company Amorphical brings a breakthrough approach to treating a variety of chronic inflammatory and oncological diseases.

Scientific Development and Breakthrough

Amorphical has developed a pioneering technology to produce amorphous nano-minerals.

The unique structure of these amorphous nano-minerals enables the efficient and rapid absorption of essential minerals in the body.

Amorphous nano-minerals also possess a unique ability to stimulate healing mechanisms within the target damaged tissues.

Amorphous Calcium Carbonate – Amorphical's Revolutionary Leading Product

Calcium is a vital mineral for various physiological activities: bone formation, nerve conductivity, muscle function, boosting the immune system, and many other activities.

Carbonate is a crucial molecule for maintaining the body's pH balance by neutralizing excess acidity.

Treating the Cause for Disease, Not Just the Symptom

Modern lifestyle, characterized by stress, unbalanced diet, and an increase in life expectancy, results in a reduced production of bicarbonate, essential for the proper function of the body. Consequently, the elevated tissue acidity impairs the ability to regulate inflammatory processes, ultimately leading to the development of chronic inflammatory as well as oncological diseases.

Due to its unique structure and dissolving properties, unlike the crystalline mineral, the amorphous calcium carbonate can directly target inflamed or cancerous tissues.

When amorphous carbonate calcium reaches the inflamed tissue, a neutralizing reaction occurs within the acidic environment. The resulting neutral environment does not support the inflammatory processes, leading to the desired healing.

Neutralizing the acidic environment is also crucial in treating oncological diseases. Most oncological diseases are characterized by anaerobic respiration of cancer cells, creating an acidic environment within the tumor. This acidic environment supports the rapid division of cancer cells and the development of metastases, while preventing the immune system from attacking and eliminating the cancer cells.

Neutralizing the acidic environment in the cancerous tissue by amorphous calcium carbonate inhibits the enhanced metabolic activity of the cancer cells, required for their rapid division.

In parallel to the reduction in cancer cell proliferation, the neutralization of the acidic environment within the tumor allows the immune cells to resume their activity, and attack and destroy the cancer cells.

To date, this is the sole technology capable of treating and curing a wide range of oncological diseases by transforming the cancerous environment into a healthy environment.

Comparison to Current Medications

Current medications for chronic inflammatory diseases primarily aim to alleviate symptoms rather than target the disease accelerator, which is the acidic environment within the inflamed tissue. In contrast, amorphous calcium carbonate neutralizes the acidic environment specifically in the inflamed tissue, and thus enables the healing of the inflammation.

Conditions Suitable for Treatment by Amorphous Calcium Carbonate

The innovative treatment with amorphous calcium carbonate promotes prompt and effective recovery across a variety of diseases:

1.  Crohn's Disease, Multiple Sclerosis, Osteoporosis, Arthritis, Pulmonary diseases, and other chronic inflammatory diseases.

2.  A wide range of oncological diseases including breast, prostate, colon, liver cancers, and  more.

3.  The treatment has proven to be highly effective in managing COVID-19.

4.  The treatment significantly slows down aging processes and substantially improves the quality of life.

Selected Scientific Publications on the Medical Activity of Amorphical's Nano-Amorphous Calcium Carbonate:

Lung Cancer:

Amorphous Calcium Carbonate Shows Anti-Cancer Properties That are Attributed to Its Buffering Capacity. Cancers (Basel). 2023 Jul 26;15(15):3785

Treatment for COVID-19:

Sublingual and Inhaled Amorphous Calcium Carbonate for Hospitalized Patients with SARS-CoV-2: A Phase 1/2 Clinical Study. J Clin Trials. 2023 Vol.13 Iss. 4 No: 1000551

Effect on Mouse Embryos:

The effect of amorphous calcium carbonate as a culture media supplement on embryonic development of murine sibling embryos. J Assist Reprod Genet. 2023 Oct;40(10):2409-2418

Additional articles describing the treatment with Amorphical's amorphous nano-minerals are presented on the company's website.

For more information, please contact: Noga Nadel Erental - [email protected]  

Logo - https://mma.prnewswire.com/media/2285885/Amorphical_Logo.jpg

SOURCE Amorphical

Modal title

Also from this source

Amorphical Announces Positive Final Long-Term Results from Phase 2 Crohn's Disease Trial: Results Confirm Efficacy and Show Sustained Clinical Remission

Amorphical, a developer of nano-amorphous mineral-based pharmacologic agents, today announced positive final long-term follow-up data from its Phase...

Amorphical Announces First Patient Enrolled in Phase 2 Clinical Trial of Nano-Amorphous Mineral-Based Therapy in Stage IV Pancreatic Cancer Patients

Amorphical, developer of nano-amorphous mineral-based pharmacologic agents for health conditions, today announced that the first patient has been...

More Releases From This Source

Explore

Health Care & Hospitals

Health Care & Hospitals

Medical Pharmaceuticals

Medical Pharmaceuticals

Clinical Trials & Medical Discoveries

Clinical Trials & Medical Discoveries

News Releases in Similar Topics

Contact PR Newswire

  • +972-77-2005042
    from 8 AM - 11 PM IL

Global Sites

  • APAC
  • APAC - Traditional Chinese
  • Asia
  • Brazil
  • Canada
  • Czech
  • Denmark
  • Finland
  • France
  • Germany

 

  • India
  • Indonesia
  • Israel
  • Italy
  • Mexico
  • Middle East
  • Middle East - Arabic
  • Netherlands
  • Norway
  • Poland

 

  • Portugal
  • Russia
  • Slovakia
  • Spain
  • Sweden
  • United Kingdom
  • United States

Do not sell or share my personal information:

  • Submit via [email protected] 
  • Call Privacy toll-free: 877-297-8921
Global Sites
  • Asia
  • Brazil
  • Canada
  • Csezh
  • Denmark
  • Finland
  • France
  • Germany
  • India
  • Israel
  • Italie
  • Mexico
  • Middle East
  • Netherlands
  • Norway
  • Poland
  • Portugal
  • Russia
  • Slovakia
  • Spain
  • Sweden
  • United Kingdom
  • United States
+972-77-2005042
from 8 AM - 11 PM IL
  • Terms of Use
  • Privacy Policy
  • Information Security Policy
  • Site Map
  • Cookie Settings
Copyright © 2025 Cision US Inc.